Zhu S, Shen Q, Gao Y, Wang L, Fang Y, Chen Y, Lu W
doi: 10.1038/nm1555 84 EndoF.KasaiA.SotoJ
KPV may be most relevant if you: Have a confirmed diagnosis of Crohn's disease or ulcerative colitis and are seeking adjunct anti-inflammatory support Manage a chronic inflammatory skin condition (eczema, psoriasis, atopic dermatitis) with incomplete response to standard treatments Have elevated systemic inflammatory markers alongside gut symptoms Are managing Mast Cell Activation Syndrome and looking for targeted cytokine modulation Have had adverse reactions to systemic immunosuppressants and need an alternative with a different mechanism KPV is likely not the right starting point if: You primarily need tissue repair rather than inflammation control (BPC-157 may be a better fit for structural gut repair) You have no active inflammatory diagnosis You are seeking peptide therapy without medical supervision Safety Profile and Limitations of the Current Evidence KPV has demonstrated a favorable safety profile in preclinical research no significant toxicity signals have emerged across two decades of animal studies
BPC-157 is non-hormonal , meaning it doesnt interact with estrogen, testosterone, or other sex hormones
Lipid metabolism is closely related to ferroptosis
